Articles from Promega Corporation

Promega Corporation has been named a BioSpace 2026 Best Place to Work. The Wisconsin biotechnology manufacturer joins 50 U.S. employers recognized on the Best Places to Work list, highlighting companies most valued by professionals across the life sciences.

Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied and pharmaceutical molecular applications.

The 36th annual International Symposium on Human Identification (ISHI) will take place November 2-6 in West Palm Beach, Florida. ISHI welcomes more than 900 forensic DNA experts and law enforcement professionals from around the world. Promega Corporation, a developer and manufacturer of products for DNA-based human identification, has sponsored ISHI since its inception.

Promega Corporation and Aobious Inc. have entered into a settlement agreement to resolve a patent infringement lawsuit related to furimazine and its associated variants. On July 15, 2025, the U.S. District Court for the District of Delaware entered a final Consent Judgment confirming that Aobious infringed four Promega patents, issuing a permanent injunction against Aobious and requiring Aobious to make monetary payments to Promega as agreed upon in the settlement terms.

Promega Corporation, a global biotechnology manufacturer headquartered in Madison, Wisconsin, has committed to set near-term company-wide emission reductions with Science Based Targets initiative (SBTi). This begins a defined process to develop science-based targets for reducing greenhouse gas (GHG) emissions across the company’s global operations.

Promega Tailored R&D Solutions (TRS) is now listed on Scientist.com and Science Exchange, two of the largest platforms for connecting labs with Contract Research Organizations (CROs) and service providers. Promega TRS is a collaborative team that helps researchers and drug discovery clients to overcome capacity, expertise and technology gaps by developing custom solutions tailored to their specific needs. Researchers can engage with Promega TRS through these platforms to initiate custom assay development projects and screening services.

Promega Corporation announced today that its headquarters in Madison, Wisconsin has achieved ISO 14001:2015 certification, an internationally recognized standard for environmental management systems. This certification reflects the biotechnology manufacturer’s longstanding commitment to environmental stewardship and sustainability.

Promega announced that the ProDx MSI Detection Kit has been awarded an innovative medical device registration certificate from the National Medical Products Administration (NMPA) in China. This kit utilizes the fluorescent PCR-capillary electrophoresis method to qualitatively detect eight microsatellite loci in tumor tissue. ProDx MSI Detection Kit will be used to characterize colorectal cancers for microsatellite instability as an aid to identify patients that would benefit from additional genetic testing to diagnose Lynch syndrome. This approval represents a key step forward in providing advanced diagnostic tools to clinical laboratories in China.

Promega technology used in the development of vaccines for infectious viral diseases will support a collaboration between Charles River and the Coalition for Epidemic Preparedness Innovations’ (CEPI’s) Centralised Laboratory Network. The Promega HiBiT-PsVLP Bioassay enables researchers to safely clone components of a virus without requiring the actual harmful virus particles. This technology will aid in advancing the collaboration’s objective to standardize and expedite the development of vaccines for epidemic and pandemic diseases, including Ebola Sudan, Marburg and other infectious viruses.

Promega Corporation announced today that it has filed a patent infringement lawsuit against Aobious, Inc. to protect its intellectual property rights regarding furimazine and its associated variants. Furimazine is a critical component of NanoLuc® luciferase technology developed by Promega, and the company holds multiple active U.S. patents protecting the structure of furimazine and its variants. With this legal action, Promega aims to halt unauthorized sales of furimazine and its derivatives.

PowerPlex® 35GY System, the first 8-color STR analysis chemistry, has been approved by the FBI for use in the National DNA Index System (NDIS). This approval indicates that the kit meets the FBI’s rigorous Quality Assurance Standards (QAS) and is suitable for generating profiles eligible for inclusion in the national database.

Promega Corporation and QuantumCyte today announced a strategic joint marketing agreement aimed at enhancing the workflow solutions available to clinical laboratories. The collaboration will focus on the joint promotion of the QuantumCyte QCPRECISE!™ precision tissue enrichment platform alongside manual and automated nucleic acid purification chemistry from Promega. The two companies will present a joint poster highlighting this workflow at the upcoming Association for Molecular Pathology 2024 Annual Meeting, November 19-23 in Vancouver.

Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, today unveils the new GloMax® Galaxy Bioluminescence Imager being showcased at the annual Society for Neuroscience (SFN) 2024 conference in Chicago October 5-9.

A novel enzyme developed by research scientists at Promega Corporation will virtually eliminate confounding stutter artifacts in forensic DNA analysis. The reduced stutter polymerase dramatically simplifies mixed sample deconvolution and allows forensic analysts to generate accurate profiles of multiple contributors. This is the first enzyme to solve one of the biggest challenges in DNA forensics.

The International Symposium on Human Identification (ISHI) will celebrate its 35th anniversary September 23—26 in San Antonio. The annual meeting on DNA forensics welcomes more than 900 forensic DNA experts and law enforcement professionals from around the world. Promega Corporation, a developer and manufacturer of products for DNA-based human identification, has sponsored ISHI since its inception.

A new DNA extraction kit will accelerate the processing of backlogged sexual assault kits by enabling labs to automate differential extraction of sperm DNA. The Maxwell DE System, launched today by Promega, is the first automated kit to eliminate the need for purification following cell separation, allowing for direct DNA quantification and STR analysis on non-sperm and sperm fractions with Promega PowerQuant® and PowerPlex® Systems. This reduces hands-on processing time, thereby accelerating sexual assault evidence kit sample processing and reducing backlogs.

Researchers working with bioluminescence now have a more accessible and cost-effective tool for their studies. The newly launched MyGlo™ Reagent Reader from Promega Corporation is a portable 96-well plate reader customized for specific Promega luminescence assays. The new device offers a wide dynamic range at a fraction of the price of a multimode reader.

Research published in Science reveals a new target for non-hormonal male contraception. The protein, a kinase called STK33, has been linked to infertility in male mice and humans. Researchers from Baylor College of Medicine, in collaboration with scientists at Promega Corporation, used DNA-Encoded Libraries (DELs) to screen billions of compounds and identify potent inhibitors that bind STK33. Their results show that STK33 inhibition produces a reversible contraceptive effect in mice, making the protein a promising sperm-specific target for further male contraceptive development. In addition, the studies show that the novel contraceptive molecule (CDD-2807) is safe when delivered to the male mice and only affects the function and morphology of the sperm.

Promega Corporation today launched its annual report on how the biotechnology manufacturer is supporting sustainability, employee wellbeing and global communities. The 2024 Promega Corporate Responsibility Report contains environmental data, summaries of key initiatives and information on how the company aligns with the United Nations Sustainable Development Goals in its global operations.

Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples. The PowerPlex® 18E System, launched by Promega Corporation, uses eight-color short tandem repeat (STR) analysis chemistry to extract more usable information from challenging samples. The kit includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).

Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers. The molecule, called SJ3149, demonstrates potent anti-proliferative activity in a variety of human cancer cell lines through selective degradation of the cancer-causing protein CK1α. The authors suggest that this degrader shows great promise for broad-spectrum anti-cancer applications.

BioLabs and Promega today announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies. Promega GmbH in Walldorf, the German branch of global life science manufacturer Promega, will provide equipment, services and training to BioLabs Heidelberg. This initiative further establishes the Rhine-Neckar region as the center of science innovation in Germany and strengthens the region’s supportive ecosystem for early-stage start-up companies.

Promega Corporation has been named a BioSpace 2024 Best Place to Work. The biotechnology manufacturer is among 60 U.S. operating employers on the Best Places to Work list that have been recognized as the most sought-after in the industry by the life sciences community.

A new study uses key Promega technologies to evaluate reported anti-inflammation molecules in the context of live cells. Promega research scientists used three unique assays to evaluate seven inhibitors targeting the NLRP3 inflammasome, a hot target in drug development for its role in multiple inflammatory diseases. The team was able to rank the potency of five reported NLRP3 inhibitors and demonstrate that two failed to produce the intended biological effects. The paper is available open access from Cell Chemical Biology.

Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly). The collaboration agreement leverages the companies’ complementary strengths to expand personalized healthcare options to more patients using high quality diagnostic tools and treatments.

The Promega Fall Art Showcase will honor the life of Truman Lowe, a visionary artist, mentor and art professor. The exhibition will feature sculptures by Lowe alongside works by several of his former students. The Fall Art Showcase opens September 19 at the BioPharmaceutical Technology Center.

A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing. The results demonstrate how this groundbreaking technique can be enhanced by using two inhibitors to boost insertion rates and reduce off-target effects. Their findings are key to advancing the use of CRISPR techniques in research and clinical applications using a wide range of cell lines.

Ten undergraduate students will receive scholarships worth up to $5,000 and mentorship from established scientists in the biotechnology industry. The Diversification Of Our Research Scientists (D.O.O.R.S.) Scholarship aims to recognize and empower students from underrepresented backgrounds who are pursuing a biotechnology-related major. The scholarship is offered by Promega Corporation and the BioPharmaceutical Technology Center Institute (BTC Institute).

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery. Reported in Cell Chemical Biology, researchers from Promega Corporation and WuXi AppTec generated new chemical probes from molecules identified through a DEL screen. This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “hit to lead” efforts in identifying new potential therapeutics.

The 34th International Symposium on Human Identification (ISHI) will welcome more than 900 forensic DNA experts and law enforcement professionals from around the world September 18-21 in Denver. Keynote speaker Allison Massari, an award-winning motivational speaker, will deliver a message on resilience and responding to difficult circumstances. Massari, who has spoken in more than 75 countries, draws on life lessons on confidence and well-being that she learned after she was severely burned in a fire.

INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a global leader in innovative technologies, tools and technical support to the life sciences industry, today announced a joint marketing agreement to co-market INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems worldwide.

Promega Corporation has committed to sourcing 100% of its global electricity usage from renewable sources by 2025. The Wisconsin-based biotechnology manufacturer will continue scaling up renewable electricity production at its facilities, partnering on local projects and purchasing renewable credits where necessary. This move supports the company’s goal of a 50% reduction in carbon emissions by 2030, as indexed to revenue over a 2019 baseline.

Glass and fiber will take center stage at the opening of the Promega Summer Art Showcase June 13 at the Promega BioPharmaceutical Technology Center in Fitchburg, WI. “Threads of Joy” explores a vast range of human experiences and emotions through works by artists Jim Smoote II, Steve Feren and Jarka Sobiskova.

Early-career researchers working with real-time quantitative PCR (qPCR) can advance their project through a grant offered by Promega Corporation. The 2023 qPCR Grant will award $15,000 in free Promega products to three academic life scientists incorporating the technique into their research. Applications will be accepted from April 3—May 5, 2023, with the recipients announced in June 2023.

The 2023 Promega Spring Art Showcase titled “ArtScience of Innovation” will explore the interplay of art and science. Works by artists Todd Siler, Nastia Craig and Monica Cliff will be on public display at the Promega BioPharmaceutical Technology Center beginning March 21.

Research published in Nature Chemical Biology demonstrates a new tool for scientists studying conditions such as autism and Alzheimer’s disease. Promega R&D scientists, alongside co-authors from Stanford Medicine, have published a paper describing the development of cephalofurimazine, a novel substrate for NanoLuc® Luciferase that enables researchers to study the brain using bioluminescence imaging. The study marks a major technological advance for research on complex neurological diseases and potential treatments.

Promega was named today as a top employer in the US for a second year in a row, winning a 2023 Top Workplaces USA award. Companies earn a place on the Top Workplaces USA list based solely on feedback from employee engagement surveys compiled by research firm Energage.

New chemistry for DNA analysis will empower forensic laboratories to overcome common challenges including degraded and contaminated samples. PowerPlex® 35GY System, launched today by Promega Corporation, is a first-of-its-kind eight-color DNA analysis kit that helps forensic laboratories get more information out of their most challenging samples. The kit works in tandem with Spectrum CE System, a capillary electrophoresis instrument launched by Promega in 2022.

Wastewater testing labs can now scale up their infectious disease surveillance using two reliable technologies in a single kit. The new system released by Promega Corporation pairs the company’s Maxwell® HT chemistry with Ceres Nanosciences’ Nanotrap® particles, an established technology for capturing and concentrating low-abundance analytes such as viral particles. Together, these technologies empower labs to purify pathogen nucleic acids from wastewater samples in high-throughput workflows.

Promega is hosting photography education non-profit PhotoMidwest to highlight the work of more than 60 Midwestern photographers. The 2022 Promega Fall Art Showcase will present the 12th Biennial PhotoMidwest Festival juried exhibition September 22 through December 2.

More than 1000 forensic DNA experts and law enforcement professionals from around the world will gather at the International Symposium on Human Identification (ISHI) October 31 – November 3 in Washington D.C. Keynote speaker DeNeen L. Brown, a reporter at The Washington Post, will discuss the Red Summer of 1919, when a reign of racist massacres swept more than 25 US cities, and the 1921 Tulsa Race Massacre. Brown's reporting prompted the City of Tulsa to reopen an investigation into the search for mass graves of Black people killed during the massacre. In 2020, scientists discovered a mass grave in the city's public cemetery.

Promega Corporation now draws over 20% of its global electricity from renewable sources. The 2022 Promega Corporate Responsibility Report, released today, details how the biotechnology company’s investments in solar arrays have led to a ten-fold increase in renewable energy usage in the last three years. The report also outlines how Promega continues to support its employees and local communities while developing technologies aimed at improving human life through scientific advancement.

Forensics laboratories performing human identification in criminal casework and database cases have a new option for a capillary electrophoresis (CE) instrument to support their workflow. The Spectrum CE System, launched today by Promega, presents a new alternative in a market that has historically featured few options for instrumentation providers. By eliminating scheduling challenges and supporting chemistry from key vendors, the instrument gives forensic analysts unmatched flexibility in how they process samples using short tandem repeat (STR) analysis.

Researchers studying immunity and inflammation now have a faster, easier alternative to traditional enzyme-linked immunosorbent assays (ELISAs) with new Promega bioluminescent assays launched today. The Lumit™ Cytokine Immunoassays can quantitatively detect released cytokines from cell culture samples in 70 minutes. These luminescent assays are scalable for use in basic research or high-throughput screening for drug discovery and development.

Life science researchers can explore new ideas for genome engineering technology through a newly announced post-doctoral research program launched by Promega with mentoring support from AstraZeneca. The program gives researchers the unique opportunity to work on groundbreaking projects in an emerging field while collaborating with scientists at a global pharmaceutical company and a manufacturer of life science research tools.

Promega Corporation was named one of the top places to work in Madison, WI, winning a Madison Top Workplaces 2022 award from The Wisconsin State Journal. Based solely on employee feedback, the biotechnology manufacturer ranked fifth among large employers in the Madison area and also received special recognition among all local employers for its support of employee work-life balance. Last month, Promega also earned a 2022 Top Workplaces USA award.

Research published today in Nature Chemical Biology reveals new opportunities for using small molecule drugs to target KRAS, the most commonly mutated protein in cancer. Promega research scientists collaborated with the University of California – San Francisco research group led by Dr. Kevan M. Shokat, a global leader in KRAS biology, to study the binding of potentially therapeutic molecules to common mutants of the KRAS protein. This study represents the first observation and quantification of direct target engagement of KRAS(G12D) and other hotspot oncogenic mutants of KRAS in cells using reversible binders.

Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors. The study, published in the February issue of Journal of Molecular Diagnostics, is the first to use the PCR-based Promega LMR MSI Analysis System to detect MSI in endometrial, prostate and other cancers.

Promega Corporation was recognized today as a top place to work in the US with a 2022 Top Workplaces USA award. Companies earn a place on the Top Workplaces USA list based solely on employee engagement surveys compiled by research firm Energage.

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation. This discovery opens new possibilities in a field that is revolutionizing drug discovery for cancer and other targets. The research is published today in Nature Chemical Biology.

Research labs performing Sanger sequencing can now use Promega chemistry on any capillary electrophoresis (CE) platform. The ProDye™ Terminator Sequencing System, launched today by Promega Corporation, can be implemented on any CE instrument, including the benchtop Spectrum Compact CE System.

Promega Corporation today launched its OncoMate™ MSI Dx Analysis System (OncoMate™ MSI) in vitro diagnostic (IVD) in the US, giving oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer. OncoMate™ MSI was cleared by the US Food and Drug Administration (FDA) last month as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

Life science and drug discovery researchers interested in bioluminescent tools will have the opportunity to hear from global thought leaders on the possibilities and applications of luciferase technologies during the upcoming Discover Glo 2021 virtual seminar series. Hosted by Promega and held September 13-16, the series will advance understanding in important therapeutic areas such as Targeted Protein Degradation and Kinase Biology.

A complete workflow developed by Promega Corporation enables wastewater testing laboratories, including public health organizations, to quickly assess the health of entire communities from a single sample. The Maxwell® RSC Enviro Total Nucleic Acid Kit and Wizard® Enviro Total Nucleic Acid Kit join a growing portfolio of products that support wastewater surveillance to monitor the spread of SARS-CoV-2.

Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors. The kit will be available to doctors in the Chinese Mainland to screen for MSI and inform immunotherapy options.

Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer. The OncoMate™ MSI Dx Analysis System (OncoMate™ MSI), developed by Promega, has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors. This is the industry's first and only PCR-based diagnostic kit for MSI characterization that is FDA-cleared for use in labs across the United States.

The International Symposium on Human Identification (ISHI) September 13-16, the world’s largest annual meeting focusing on DNA forensics, will mark the 20th anniversary of the September 11th terrorist attacks in the United States. Keynote speaker Mark Desire, Assistant Director, New York City Office of the Chief Medical Examiner (OCME), will speak to the hardship and perseverance of OCME forensic scientists and families of World Trade Center victims, as well as ongoing work to identify all who lost their lives that day. A panel will also discuss advances in forensic science worldwide that have resulted from two decades of the 9/11 investigation.

Promega Corporation is setting its most ambitious sustainability targets in the biotechnology manufacturer’s more than 40-year history. The 2021 Corporate Responsibility Report, released today, features new 2030 Environmental Improvement Goals alongside stories of how Promega is supporting researchers, employees and communities during the COVID-19 pandemic.

A SARS-CoV-2 antibody test developed by Promega Corporation, the Lumit™ Dx SARS-CoV-2 Immunoassay, has received CE marking and is now available in Europe. The novel bioluminescent immunoassay is a qualitative in vitro diagnostic test intended to detect antibodies to SARS-CoV-2 in serum.

Biotech and pharma labs performing endpoint polymerase chain reaction (PCR) can amplify samples in as little as 15 minutes with new Promega GoTaq® Rapid Master Mix paired with the Eppendorf Mastercycler® X50s thermal cycler. The combination offers one of the fastest endpoint PCR solutions on the market.

Serious runners and casual walkers alike are invited to join a month-long Get Your Rear in Gear® - Madison run/walk virtual event during May to raise money and awareness for colorectal cancer screening efforts. Colorectal cancer is the nation’s No. 2 cancer killer, but it is up to 95% preventable with proper screening. The number of people being screened has dropped drastically worldwide since the start of the COVID-19 pandemic. The event is aimed to help encourage this important, life-saving health screening.